JP2010522152A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522152A5 JP2010522152A5 JP2009554083A JP2009554083A JP2010522152A5 JP 2010522152 A5 JP2010522152 A5 JP 2010522152A5 JP 2009554083 A JP2009554083 A JP 2009554083A JP 2009554083 A JP2009554083 A JP 2009554083A JP 2010522152 A5 JP2010522152 A5 JP 2010522152A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- bone
- compound according
- ring
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 14
- 206010061218 Inflammation Diseases 0.000 claims 12
- 230000004054 inflammatory process Effects 0.000 claims 12
- 206010065687 Bone loss Diseases 0.000 claims 10
- 230000004913 activation Effects 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 125000005842 heteroatoms Chemical group 0.000 claims 8
- 125000001931 aliphatic group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 208000003432 Bone Disease Diseases 0.000 claims 6
- 210000000987 Immune System Anatomy 0.000 claims 6
- 206010023203 Joint destruction Diseases 0.000 claims 6
- 210000002997 Osteoclasts Anatomy 0.000 claims 6
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 6
- 230000002148 osteoclast Effects 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 229920000728 polyester Polymers 0.000 claims 5
- 208000006386 Bone Resorption Diseases 0.000 claims 4
- 108010002352 Interleukin-1 Proteins 0.000 claims 4
- 102000000589 Interleukin-1 Human genes 0.000 claims 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 201000001146 Paget's disease of bone Diseases 0.000 claims 4
- 102000014128 RANK Ligand Human genes 0.000 claims 4
- 108010025832 RANK Ligand Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 4
- 230000024279 bone resorption Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000001404 mediated Effects 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 2
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 208000001493 Bone Neoplasms Diseases 0.000 claims 2
- 206010020583 Hypercalcaemia Diseases 0.000 claims 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 230000001472 cytotoxic Effects 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 200000000018 inflammatory disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000004579 marble Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- 210000000056 organs Anatomy 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000004681 psoriasis Diseases 0.000 claims 2
- 201000001263 psoriatic arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 0 *N([Al]I*)S([Al][Al]I)(=O)=O Chemical compound *N([Al]I*)S([Al][Al]I)(=O)=O 0.000 description 12
- SPTJCYWEGIYIJX-UCNYIJHQSA-N C/C=C(/C1C=CC(S(/N=C2\C=CC=C(CCCO)C2)(=O)=O)=CC=C1)\C(\F)=C/C(F)=C Chemical compound C/C=C(/C1C=CC(S(/N=C2\C=CC=C(CCCO)C2)(=O)=O)=CC=C1)\C(\F)=C/C(F)=C SPTJCYWEGIYIJX-UCNYIJHQSA-N 0.000 description 1
- IRADXTURDJBIPE-UHFFFAOYSA-N C=C(C1)C(c(ccc(Cl)c2)c2Cl)=CC=C1S(Nc1cc(CCO)ccc1)(=O)=[U] Chemical compound C=C(C1)C(c(ccc(Cl)c2)c2Cl)=CC=C1S(Nc1cc(CCO)ccc1)(=O)=[U] IRADXTURDJBIPE-UHFFFAOYSA-N 0.000 description 1
- YUFKSFFAHGRLQJ-UHFFFAOYSA-N Cc(cc1)ccc1-c(cc1)ccc1S(Nc1cccc(CO)c1)(=N)=O Chemical compound Cc(cc1)ccc1-c(cc1)ccc1S(Nc1cccc(CO)c1)(=N)=O YUFKSFFAHGRLQJ-UHFFFAOYSA-N 0.000 description 1
- YOGYLSSOGBIQMI-UHFFFAOYSA-N OCc(cc1)c(CO)cc1NS(c(cc1)ccc1-c(ccc(Cl)c1)c1Cl)(=O)=O Chemical compound OCc(cc1)c(CO)cc1NS(c(cc1)ccc1-c(ccc(Cl)c1)c1Cl)(=O)=O YOGYLSSOGBIQMI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0705400.0A GB0705400D0 (en) | 2007-03-21 | 2007-03-21 | Therapeutic compounds andm their use |
| GB0705400.0 | 2007-03-21 | ||
| PCT/GB2008/000989 WO2008114022A1 (en) | 2007-03-21 | 2008-03-20 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010522152A JP2010522152A (ja) | 2010-07-01 |
| JP2010522152A5 true JP2010522152A5 (US07846941-20101207-C00217.png) | 2011-05-06 |
| JP5450105B2 JP5450105B2 (ja) | 2014-03-26 |
Family
ID=38024559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554083A Active JP5450105B2 (ja) | 2007-03-21 | 2008-03-20 | ビフェニル−４−イル−スルホン酸アリールアミド及びその治療剤としての使用 |
Country Status (11)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817208D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| EP2616450B1 (en) | 2010-09-17 | 2018-05-02 | Kancera AB | Sulfonamide compounds |
| US10941109B2 (en) | 2011-06-13 | 2021-03-09 | Ergon Pharmaceuticals Llc | Compositions and methods of treatment using a BCAT1 inhibitor |
| US9422224B2 (en) | 2011-06-13 | 2016-08-23 | Ergon Pharmaceuticals Llc | Methods of treatment using a BCAT1 inhibitor |
| WO2013055793A1 (en) | 2011-10-12 | 2013-04-18 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
| EP2794009B1 (en) * | 2011-12-22 | 2017-08-30 | Kancera AB | Bisarylsulfonamides useful in the treatment of inflammation and cancer |
| KR20150092162A (ko) * | 2012-12-10 | 2015-08-12 | 에프. 호프만-라 로슈 아게 | RORc 조절인자로서 벤질 설폰아미드 유도체 |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| JP6564380B2 (ja) | 2013-09-20 | 2019-08-21 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 前立腺癌を治療するための化合物 |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| HRP20211877T1 (hr) * | 2014-12-17 | 2022-03-04 | Pimco 2664 Limited | Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba |
| US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| KR102457657B1 (ko) | 2017-02-07 | 2022-10-21 | 리프스톤 비.브이. | 무균성 해리로 인한 임플란트 관련 임플란트 교정 위험을 진단하기 위한 바이오마커 |
| US11555012B2 (en) * | 2018-11-09 | 2023-01-17 | Nimbus Artemis, Inc. | ACLY inhibitors and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB597810A (en) | 1943-04-12 | 1948-02-04 | Gen Printing Ink Corp | Improvements in or relating to derivatives of diphenyl |
| DE1046220B (de) | 1956-04-21 | 1958-12-11 | Bayer Ag | Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen |
| US4119784A (en) | 1977-07-01 | 1978-10-10 | American Cyanamid Company | Anionic substituted sulfonamido biphenyls |
| GB2001307A (en) * | 1977-07-01 | 1979-01-31 | American Cyanamid Co | Sulphonamide blood complement inhibitors |
| DE3000519A1 (de) | 1979-02-01 | 1980-08-14 | Byk Gulden Lomberg Chem Fab | Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel |
| DE3535167A1 (de) | 1985-10-02 | 1987-04-09 | Boehringer Mannheim Gmbh | Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| EP0934291A1 (en) | 1995-10-30 | 1999-08-11 | Smithkline Beecham Corporation | Protease inhibitors |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| AU2421797A (en) | 1996-03-15 | 1997-10-01 | Du Pont Pharmaceuticals Company | Spirocycle integrin inhibitors |
| WO1998003166A1 (en) | 1996-07-22 | 1998-01-29 | Monsanto Company | Thiol sulfonamide metalloprotease inhibitors |
| BR9712525A (pt) | 1996-10-16 | 1999-10-19 | American Cyanamid Co | O preparo e uso de ácidos orto-sulfonamido aril hidroxmicos como inibidores da metaloproteinase matricial e da tace |
| WO1998023608A1 (en) | 1996-11-27 | 1998-06-04 | Dupont Pharmaceuticals Company | Novel integrin receptor antagonists |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| WO1998050342A1 (en) | 1997-05-08 | 1998-11-12 | Smithkline Beecham Corporation | Protease inhibitors |
| EP0877019B1 (de) | 1997-05-09 | 2001-12-12 | Hoechst Aktiengesellschaft | Substituierte Diaminocarbonsäuren |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| NZ505613A (en) | 1998-01-23 | 2002-11-26 | Aventis Pharma Gmbh | Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| HUP0101176A3 (en) | 1998-02-04 | 2002-06-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
| JPH11246527A (ja) | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Ｍｍｐ−８阻害剤 |
| EP0960882A1 (en) | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| CA2404236A1 (en) | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Carbocyclic side chain containing, n-substituted metalloprotease inhibitors |
| US6723733B2 (en) | 2000-05-19 | 2004-04-20 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
| AU2002228316A1 (en) | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| US20050119305A1 (en) | 2001-03-21 | 2005-06-02 | Masao Naka | Il-6 production inhibitors |
| WO2002089785A1 (en) * | 2001-05-07 | 2002-11-14 | Smithkline Beecham Corporation | Sulfonamides |
| KR20040022238A (ko) | 2001-08-09 | 2004-03-11 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체 화합물 및 그 화합물을 유효성분으로서 함유하는 약제 |
| GB0126157D0 (en) * | 2001-10-31 | 2002-01-02 | Univ Aberdeen | Therapeutic compounds |
| EP1491190A4 (en) | 2002-03-27 | 2006-01-04 | Shionogi & Co | DECOMPOSITION INHIBITOR FOR CARTRIDGE EXTRACELLULAR MATRIX |
| KR101088922B1 (ko) | 2002-09-04 | 2011-12-01 | 파마코페이아, 엘엘씨. | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
| DE10251170A1 (de) * | 2002-10-31 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004073619A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| DE602004010514T2 (de) * | 2003-05-07 | 2008-11-27 | The University Court Of The University Of Aberdeen, Aberdeen | Ketone und reduzierte ketone als therapeutische mittel zur behandlung von knochenerkrankungen |
| WO2004106290A1 (ja) | 2003-05-14 | 2004-12-09 | Kissei Pharmaceutical Co., Ltd. | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| AP2006003633A0 (en) | 2003-12-19 | 2006-06-30 | Pfizer | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-BETA-hydroxysteroid dehydrogenase type 1 (11-BETA-HSD-1) for the treatment of diabetes and obesity |
| EP1723132A1 (en) | 2004-02-12 | 2006-11-22 | Asterand Uk Limited | Ep2 receptor agonists |
| GB0405193D0 (en) * | 2004-03-08 | 2004-04-21 | Medical Res Council | Compounds |
| WO2005105712A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Sulfonamide derivatives |
| GB0412553D0 (en) | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| WO2005123089A2 (en) | 2004-06-10 | 2005-12-29 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| MX2007016319A (es) | 2005-06-16 | 2008-03-10 | Pfizer | Derivados de n-(piridin-2-il)-sulfonamida. |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| TW200720261A (en) | 2005-08-31 | 2007-06-01 | Sankyo Co | Phenylene derivatives |
| ES2395392T3 (es) * | 2005-12-29 | 2013-02-12 | Lexicon Pharmaceuticals, Inc. | Derivados aminoácidos multicíclicos y métodos de su uso |
| US7560597B2 (en) * | 2007-03-08 | 2009-07-14 | The University Court Of The University Of Aberdeen | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
-
2007
- 2007-03-21 GB GBGB0705400.0A patent/GB0705400D0/en not_active Ceased
-
2008
- 2008-03-20 HU HUE08718826A patent/HUE028656T2/en unknown
- 2008-03-20 EP EP08718826.4A patent/EP2137141B1/en active Active
- 2008-03-20 US US12/531,732 patent/US8524778B2/en active Active
- 2008-03-20 WO PCT/GB2008/000989 patent/WO2008114022A1/en active Application Filing
- 2008-03-20 CA CA2681320A patent/CA2681320C/en active Active
- 2008-03-20 SI SI200831582T patent/SI2137141T1/sl unknown
- 2008-03-20 DK DK08718826.4T patent/DK2137141T3/en active
- 2008-03-20 ES ES08718826.4T patent/ES2561163T3/es active Active
- 2008-03-20 JP JP2009554083A patent/JP5450105B2/ja active Active
-
2016
- 2016-02-22 HR HRP20160183T patent/HRP20160183T1/hr unknown
